A Phase I, Open Label, Single-Dose, Randomized, Four-Way Crossover Study to Compare the Pharmacokinetics of NP101 (Sumatriptan Iontophoretic Transdermal Patch) With an Oral Formulation of Imitrex [sumatriptan] in Migraine Subjects During an Acute Migraine Attack and a Non-Migraine Period.

Trial Profile

A Phase I, Open Label, Single-Dose, Randomized, Four-Way Crossover Study to Compare the Pharmacokinetics of NP101 (Sumatriptan Iontophoretic Transdermal Patch) With an Oral Formulation of Imitrex [sumatriptan] in Migraine Subjects During an Acute Migraine Attack and a Non-Migraine Period.

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Apr 2012

At a glance

  • Drugs Sumatriptan (Primary) ; Sumatriptan (Primary)
  • Indications Migraine
  • Focus Pharmacokinetics
  • Most Recent Events

    • 25 Apr 2012 Actual patient number (23) added as reported by ClinicalTrials.gov.
    • 12 Feb 2010 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
    • 12 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top